[1] FDA. E15 Pharmacogenomics Definitions and Sample Coding[EB/OL].(2008-04-07)[2017-08-08].https://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM073162. [2] 赵楠, 张亚同, 程刚,等. 药物基因组学在临床试验中的应用[J]. 中国新药杂志, 2013,22(1):30-33. [3] 王涛, 王丹, 董铎, 等. 美国药物警戒体系浅析及对我国的启示[J]. 医药导报, 2017, 36(4):361-365. [4] FDA. Search for FDA Guidance Documents[EB/OL].(2017-05-17)[2017-08-08]. https://www.fda.gov/RegulatoryInformation/Guidances/default.htm. [5] FDA. Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling[EB/OL].(2013-01-29)[2017-08-08].https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM337169. [6] 娄莹, 刘红, 韩璐璐, 等. CYP2C9和VKORC1基因多态性对肺栓塞患者华法林维持剂量的影响[J]. 中国药物警戒, 2012, 9(4):202-204. [7] Zineh I, Pacanowski M A. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration[J]. Pharmacotherapy, 2011,31(8):729-735. [8] Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir[J].N Engl J Med, 2008, 358(6):568-579. [9] Mega J L, Close S L, Wiviott S D, et al. Cytochrome p-450 polymorphisms and response to clopidogrel[J]. N Engl J Med, 2009, 360(4):354-362. [10] Mega J L, Close S L, Wiviott S D, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis[J].Lancet, 2010, 376(9749):1312-1319. [11] ZinehIssam. Personalized medicine: A biological approach to patient treatment[EB/OL]. (2016-02-26)[2017-08-08]. https://www.fda.gov/Drugs/NewsEvents/ucm325475.htm. [12] 耿春梅, 郭瑞臣. 药物基因组学在新药临床试验及个体化用药中的应用[J]. 药学进展, 2015, 39(11):803-809. [13] 孙可欣, 詹思延, 胡永华. 医学大数据在药物基因组学领域中的应用与发展[J]. 药物流行病学杂志, 2017, 26(1):68-73. [14] 张亚同, 梁欣, 孙迎琪, 等. 药物基因组学基础的药物警戒研究进展[J]. 中国药物警戒, 2010, 7(8):486-489. [15] 刘飞,辛华雯. 药物基因组学与临床药师[J]. 医药导报, 2017, 36(9): 956-961. |